Review
Highlights
- •
- Platinum-taxane chemotherapy remains the standard of care for the primary treatment of optimally cytoreduced advanced epithelial ovarian cancer
- •
- Primary intraperitoneal cisplatin-based chemotherapy has been shown to improve survival in the setting of optimal residual advanced ovarian cancer
- •
- The role of bevacizumab in the primary anti-neoplastic drug management of optimal residual advanced ovarian cancer remains to be defined
"There
has been limited change in evidence-based primary chemotherapeutic
management of optimal residual advanced ovarian cancer for more than a
decade. The backbone of therapy remains a platinum agent (generally
carboplatin) and a taxane (generally paclitaxel). Phase 3 randomized
trial data provide support for the use of weekly paclitaxel in this
setting (compared to the traditional every 3-week schedule) and the
addition of bevacizumab as a component of primary management. Recently
available data provide increasingly solid support for a role of regional
platinum administration in at least a subset of patients with optimal
residual advanced ovarian cancer and an important retrospective analysis
has suggested a novel biomarker that may predict for the utility (or
lack thereof) of this method of drug delivery."
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.